Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and PK of [14C]-Risdiplam in Healthy Males
NCT03036501Phase 1Completed
- Sponsor
- Roche
- Start
- Jan 2017
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of risdiplam in spinal muscular atrophy (SMA), sponsored by Roche. Primary endpoints: Percentage of Dose Recovered as Total [14C]-radioactivity in Urine, Cumulative Urinary Amount of Total [14C]-Radioactivity in Urine and 6 more. Started Jan 2017; status: completed.
02
Drugs
risdiplam
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT03036501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03036501.